Compare iShares MSCI ACWI ETF (ACWI) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Enveric Biosciences Inc — how do they compare? iShares MSCI ACWI ETF trades at $160.86, while Enveric Biosciences Inc trades at $1.45 (market cap $6.20M). The key difference: iShares MSCI ACWI ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ACWI | ENVB | |
|---|---|---|
52-Week High | $161.44 | $17.40 |
52-Week Low | $131.51 | $1.27 |
Market Cap | — | $6.20M |
Sector | — | Health |
Enterprise Value | — | $1.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI (iShares MSCI ACWI ETF) trades at $161.44, up 0.84% with a bullish technical signal from moving averages, though oscillators show caution. The ETF benefits from strong global earnings growth and a forward P/E of 15.5x as of Seeking Alpha on July 7, 2026. Recent institutional activity includes Bank of New York Mellon adjusting its stake, reflecting ongoing investor interest in global equity exposure, particularly in technology sectors.
The outlook for ACWI is supported by robust EPS growth and technical momentum, but risks include market volatility and sector concentration. Investors may find opportunity in its diversified global holdings, though overbought conditions near resistance at $162 warrant monitoring for pullbacks to support at $160.
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
